“Observations on the predictive power of a high-throughput and high complexity CLIA-certified assay to guide therapy selection for cancer patients“
Carla Grandori, MD, PhD
Co-founder and CEO, SEngine Precision Medicine
Dr. Grandori received her MD from the University of Rome, La Sapienza, followed by a PhD in Molecular Biology and Biochemistry at The Rockefeller University in NY. Her PhD thesis led to identifying the key mutations and molecular functions of the tyrosine kinase (TK) oncogenes and to pioneering the generation of antibodies recognizing P-tyrosine-containing proteins in cancer. This was a new tool to delineate targets of TK oncoproteins on cancer cells, such as BCR-ABL, HER2, and many other cancer drivers. After completing her post-doctoral fellowship at MIT in Cambridge, Dr. Grandori joined the Fred Hutchinson Cancer Research Center in Seattle, this time focused on another oncoprotein, the transcription factor MYC. Dr. Grandori leveraged chromatin immunoprecipitation (ChIP) technology to map MYC binding sites on the cancer genome and subsequently genome-wide microarrays to delineate MYC induced transcriptional program. Embracing and perfecting another technological breakthrough, high-throughput functional genomics, Dr. Grandori’s laboratory at the Fred Hutch identified and characterized a comprehensive set of MYC synthetic lethal gene pairs as novel candidates for drug development.
In 2015, Dr. Grandori co-founded SEngine Precision Medicine and has worked full time as CEO/CSO to apply these technologies to improve the efficiency of developing new drugs and to personalize cancer treatments. SEngine Precision Medicine has since developed the PARIS® Test, a next-generation diagnostic assay employing patient-derived models, mainly 3D organoids, to define drug sensitivity for individual patients across a broad menu of oncology drugs. The PARIS® Test is a CLIA certified assay and it is now available to oncologists.
Meeting ID: 865 5988 5672; Passcode: uz7ss15g
Meeting agenda includes a presentation, programmatic announcements and updates from program leaders. This group meets on second Tuesday of every month from 4:00 p.m. – 5:00 p.m.